Daniel M Kerekes, Alexander E Frey, Elizabeth H Prsic, Thuy T Tran, James E Clune, Mario Sznol, Harriet M Kluger, Howard P Forman, Robert D Becher, Kelly L Olino, Sajid A Khan
IMPORTANCE: While immunotherapy is being used in an expanding range of clinical scenarios, the incidence of immunotherapy initiation at the end of life (EOL) is unknown. OBJECTIVE: To describe patient characteristics, practice patterns, and risk factors concerning EOL-initiated (EOL-I) immunotherapy over time. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using a US national clinical database of patients with metastatic melanoma, non-small cell lung cancer (NSCLC), or kidney cell carcinoma (KCC) diagnosed after US Food and Drug Administration approval of immune checkpoint inhibitors for the treatment of each disease through December 2019...
March 1, 2024: JAMA Oncology